Xtant Medical Holdings Inc
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety thro… Read more
Xtant Medical Holdings Inc (XTNT) - Net Assets
Latest net assets as of September 2025: $50.38 Million USD
Based on the latest financial reports, Xtant Medical Holdings Inc (XTNT) has net assets worth $50.38 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($106.32 Million) and total liabilities ($55.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $50.38 Million |
| % of Total Assets | 47.39% |
| Annual Growth Rate | 67.36% |
| 5-Year Change | 196.01% |
| 10-Year Change | 384.01% |
| Growth Volatility | 12964.87 |
Xtant Medical Holdings Inc - Net Assets Trend (2008–2024)
This chart illustrates how Xtant Medical Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xtant Medical Holdings Inc (2008–2024)
The table below shows the annual net assets of Xtant Medical Holdings Inc from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $42.96 Million | -16.33% |
| 2023-12-31 | $51.35 Million | +50.27% |
| 2022-12-31 | $34.17 Million | +10.65% |
| 2021-12-31 | $30.88 Million | +112.78% |
| 2020-12-31 | $14.51 Million | +132.83% |
| 2019-12-31 | $-44.20 Million | -0.99% |
| 2018-12-31 | $-43.77 Million | +25.43% |
| 2017-12-31 | $-58.70 Million | -729.87% |
| 2016-12-31 | $-7.07 Million | -179.69% |
| 2015-12-31 | $8.88 Million | +214.17% |
| 2014-12-31 | $-7.77 Million | -102.36% |
| 2013-12-31 | $-3.84 Million | -190.78% |
| 2012-12-31 | $4.23 Million | -23.06% |
| 2011-12-31 | $5.50 Million | +988.35% |
| 2010-12-31 | $-619.24K | -113.22% |
| 2009-12-31 | $4.68 Million | +41209.18% |
| 2008-12-31 | $11.34K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xtant Medical Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25945094400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-316.00K | -0.74% |
| Other Components | $302.74 Million | 704.65% |
| Total Equity | $42.96 Million | 100.00% |
Xtant Medical Holdings Inc Competitors by Market Cap
The table below lists competitors of Xtant Medical Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ecos India Mobility & Hospitality Ltd
NSE:ECOSMOBLTY
|
$27.30 Million |
|
Excellon Resources Inc
PINK:EXNRF
|
$27.31 Million |
|
Everyday People Financial Corp.
V:EPF
|
$27.31 Million |
|
Icecure Medical
NASDAQ:ICCM
|
$27.32 Million |
|
Shangri-La Hotel Public Company Limited
BK:SHANG
|
$27.26 Million |
|
Keyrus SA
PA:ALKEY
|
$27.26 Million |
|
Gladiator Metals Corp
PINK:GDTRF
|
$27.26 Million |
|
Kayee International Group Co Ltd
TW:2939
|
$27.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xtant Medical Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 51,349,000 to 42,963,000, a change of -8,386,000 (-16.3%).
- Net loss of 16,449,000 reduced equity.
- New share issuances of 4,456,000 increased equity.
- Other comprehensive income decreased equity by 345,000.
- Other factors increased equity by 3,952,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.45 Million | -38.29% |
| Share Issuances | $4.46 Million | +10.37% |
| Other Comprehensive Income | $-345.00K | -0.8% |
| Other Changes | $3.95 Million | +9.2% |
| Total Change | $- | -16.33% |
Book Value vs Market Value Analysis
This analysis compares Xtant Medical Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.88x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.89x to 1.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $0.05 | $0.60 | x |
| 2009-12-31 | $19.33 | $0.60 | x |
| 2010-12-31 | $-2.10 | $0.60 | x |
| 2011-12-31 | $15.42 | $0.60 | x |
| 2012-12-31 | $10.88 | $0.60 | x |
| 2013-12-31 | $-8.82 | $0.60 | x |
| 2014-12-31 | $-14.25 | $0.60 | x |
| 2015-12-31 | $10.70 | $0.60 | x |
| 2016-12-31 | $-6.65 | $0.60 | x |
| 2017-12-31 | $-38.65 | $0.60 | x |
| 2018-12-31 | $-3.70 | $0.60 | x |
| 2019-12-31 | $-3.36 | $0.60 | x |
| 2020-12-31 | $0.51 | $0.60 | x |
| 2021-12-31 | $0.36 | $0.60 | x |
| 2022-12-31 | $0.36 | $0.60 | x |
| 2023-12-31 | $0.40 | $0.60 | x |
| 2024-12-31 | $0.32 | $0.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xtant Medical Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.03%
- • Asset Turnover: 1.25x
- • Equity Multiplier: 2.18x
- Recent ROE (-38.29%) is below the historical average (-36.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -139.71% | -3.45% | 3.29x | 12.32x | $-16.98K |
| 2009 | -88.07% | -55.80% | 0.71x | 2.24x | $-4.59 Million |
| 2010 | 0.00% | -126.27% | 0.98x | 0.00x | $-19.41 Million |
| 2011 | -54.65% | -9.97% | 1.30x | 4.21x | $-3.56 Million |
| 2012 | -182.26% | -23.39% | 0.96x | 8.15x | $-8.14 Million |
| 2013 | 0.00% | -38.38% | 1.15x | 0.00x | $-12.31 Million |
| 2014 | 0.00% | -29.74% | 1.26x | 0.00x | $-9.73 Million |
| 2015 | -24.50% | -3.66% | 0.41x | 16.12x | $-3.06 Million |
| 2016 | 0.00% | -21.66% | 0.62x | 0.00x | $-18.79 Million |
| 2017 | 0.00% | -63.44% | 0.78x | 0.00x | $-46.54 Million |
| 2018 | 0.00% | -97.09% | 1.56x | 0.00x | $-65.72 Million |
| 2019 | 0.00% | -12.71% | 1.50x | 0.00x | $-3.80 Million |
| 2020 | -48.39% | -13.17% | 1.29x | 2.86x | $-8.47 Million |
| 2021 | -15.70% | -8.77% | 1.01x | 1.77x | $-7.94 Million |
| 2022 | -24.83% | -14.64% | 0.96x | 1.76x | $-11.90 Million |
| 2023 | 1.29% | 0.72% | 0.99x | 1.80x | $-4.47 Million |
| 2024 | -38.29% | -14.03% | 1.25x | 2.18x | $-20.75 Million |
Industry Comparison
This section compares Xtant Medical Holdings Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xtant Medical Holdings Inc (XTNT) | $50.38 Million | -139.71% | 1.11x | $27.29 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |